Oppenheimer assumed coverage on shares of enGene (NASDAQ:ENGN – Free Report) in a research note published on Wednesday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $30.00 price objective on the stock.
enGene Price Performance
Shares of enGene stock opened at $6.98 on Wednesday. The company has a market capitalization of $308.28 million, a P/E ratio of -4.28 and a beta of -0.63. The business has a 50-day moving average of $7.91 and a two-hundred day moving average of $12.04. enGene has a 1 year low of $4.94 and a 1 year high of $43.00.
enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Friday, June 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.14). On average, equities analysts anticipate that enGene will post -1.33 EPS for the current fiscal year.
Hedge Funds Weigh In On enGene
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
- Five stocks we like better than enGene
- EV Stocks and How to Profit from Them
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MarketBeat Week in Review – 8/26 – 8/30
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Why Dell Can Continue Winning in AI and Beyond
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.